Launch One Acquisition Corp. Unit (LPAAU)
Company News
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics received FDA Fast Track Designation for MNV-201, its investigational compound targeting Myelodysplastic Syndrome (MDS), potentially accelerating drug development and review process.